Literature DB >> 18172037

Angiotensin II activates signal transducer and activators of transcription 3 via Rac1 in atrial myocytes and fibroblasts: implication for the therapeutic effect of statin in atrial structural remodeling.

Chia-Ti Tsai1, Ling-Ping Lai, Kuan-Ting Kuo, Juey-Jen Hwang, Chia-Shan Hsieh, Kuan-Lih Hsu, Chuen-Den Tseng, Yung-Zu Tseng, Fu-Tien Chiang, Jiunn-Lee Lin.   

Abstract

BACKGROUND: Recently, activation of the local renin-angiotensin system and mitogen-activated protein kinase pathways in atrial myocardium has been found to play an important role in atrial structural remodeling related to atrial fibrillation. Another important mediator of the angiotensin II (Ang II) effect is the Janus kinase/signal transducers and activators of transcription (STAT) pathway, which has never been characterized in the atrium. METHODS AND
RESULTS: In cultured atrial myocytes and fibroblasts, Ang II induced tyrosine phosphorylation of STAT3 through a Rac1-dependent mechanism, which was inhibited by dominant-negative Rac1, losartan, and simvastatin. In atrial myocytes, activation of STAT3 by Rac1 was mediated by direct association of Rac1 with STAT3; however, in atrial fibroblasts, it was mediated by an indirect paracrine effect. Constitutively active STAT3 increased protein synthesis, and dominant-negative STAT3 abrogated Ang II-induced protein synthesis in atrial myocytes and fibroblasts. Rats infused long term with Ang II exhibited higher levels of activated Rac1, phospho-STAT3, collagen synthesis, and atrial fibrosis in the atria, all of which were attenuated by oral losartan and simvastatin. In human atrial tissues from patients with atrial fibrillation, Ang II and phospho-STAT3 levels were also elevated.
CONCLUSIONS: The Ang II/Rac1/STAT3 pathway is an important signaling pathway in the atrial myocardium to mediate atrial structural remodeling, and losartan and statin may be able to reverse Ang II-induced atrial structural remodeling in atrial fibrillation.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18172037     DOI: 10.1161/CIRCULATIONAHA.107.695346

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  39 in total

1.  Angiotensin II in atrial structural remodeling: the role of Ang II/JAK/STAT3 signaling pathway.

Authors:  Liuying Zheng; Xiaogang Jia; Cheng Zhang; Dong Wang; Zhongnan Cao; Jin Wang; Xinping Du
Journal:  Am J Transl Res       Date:  2015-06-15       Impact factor: 4.060

2.  Transgenic expression of an altered angiotensin type I AT1 receptor resulting in marked modulation of vascular type I collagen.

Authors:  Jun Yu; Linda Taylor; Celeste Rich; Paul Toselli; Philip Stone; Daniel Green; Rod Warburton; Nicholas Hill; Ronald Goldstein; Peter Polgar
Journal:  J Cell Physiol       Date:  2012-05       Impact factor: 6.384

3.  Activation of multiple signaling pathways causes developmental defects in mice with a Noonan syndrome–associated Sos1 mutation.

Authors:  Peng-Chieh Chen; Hiroko Wakimoto; David Conner; Toshiyuki Araki; Tao Yuan; Amy Roberts; Christine E Seidman; Roderick Bronson; Benjamin G Neel; Jonathan G Seidman; Raju Kucherlapati
Journal:  J Clin Invest       Date:  2010-12       Impact factor: 14.808

Review 4.  Novel pharmacological targets for the rhythm control management of atrial fibrillation.

Authors:  Alexander Burashnikov; Charles Antzelevitch
Journal:  Pharmacol Ther       Date:  2011-08-17       Impact factor: 12.310

5.  Inhibition of farnesyl pyrophosphate synthase prevents angiotensin II-induced cardiac fibrosis in vitro.

Authors:  Z Li; X Bi; M Wang; J Zhang; J Song; X Shen; J Han; G Fu; Y Ye
Journal:  Clin Exp Immunol       Date:  2014-06       Impact factor: 4.330

6.  The effect and molecular mechanism of statins on the expression of human anti-coagulation genes.

Authors:  Sheng-Nan Chang; Cho-Kai Wu; Ling-Ping Lai; Fu-Tien Chiang; Juey-Jen Hwang; Chia-Ti Tsai
Journal:  Cell Mol Life Sci       Date:  2019-05-03       Impact factor: 9.261

Review 7.  Pleiotropic effects of statins in atrial fibrillation patients: the evidence.

Authors:  Hadi Ar Hadi; Wael Al Mahmeed; Jassim Al Suwaidi; Samer Ellahham
Journal:  Vasc Health Risk Manag       Date:  2009-06-29

8.  Role of nuclear unphosphorylated STAT3 in angiotensin II type 1 receptor-induced cardiac hypertrophy.

Authors:  Hong Yue; Wei Li; Russell Desnoyer; Sadashiva S Karnik
Journal:  Cardiovasc Res       Date:  2010-01-01       Impact factor: 10.787

Review 9.  New pharmacological strategies for the treatment of atrial fibrillation.

Authors:  Alexander Burashnikov; Charles Antzelevitch
Journal:  Ann Noninvasive Electrocardiol       Date:  2009-07       Impact factor: 1.468

10.  Induction of the cytoprotective enzyme heme oxygenase-1 by statins is enhanced in vascular endothelium exposed to laminar shear stress and impaired by disturbed flow.

Authors:  Faisal Ali; Mustafa Zakkar; Kersti Karu; Elaine A Lidington; Shahir S Hamdulay; Joseph J Boyle; Mire Zloh; Andrea Bauer; Dorian O Haskard; Paul C Evans; Justin C Mason
Journal:  J Biol Chem       Date:  2009-05-19       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.